CompletedPhase 3NCT03998163
CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Studying Uremic pruritus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cara Therapeutics, Inc.
- Principal Investigator
- Frédérique Menzaghi, PhD, DDSCara Therapeutics
- Intervention
- CR845 0.5 mcg/kg(drug)
- Enrollment
- 222 enrolled
- Eligibility
- 18-85 years · All sexes
- Timeline
- 2019 – 2020
Study locations (30)
- Cara Therapeutics Study Site, Escondido, California, United States
- Cara Therapeutics Study Site, Riverside, California, United States
- Cara Therapeutics Study Site, San Diego, California, United States
- Cara Therapeutics Study Site, Victorville, California, United States
- Cara Therapeutics Study Site, Denver, Colorado, United States
- Cara Therapeutics Study Site, Middlebury, Connecticut, United States
- Cara Therapeutics Study Site, Norwich, Connecticut, United States
- Cara Therapeutics Study Site, Coral Gables, Florida, United States
- Cara Therapeutics Study Site, Fort Lauderdale, Florida, United States
- Cara Therapeutics Study Site, Hollywood, Florida, United States
- Cara Therapeutics Study Site, Miami, Florida, United States
- Cara Therapeutics Study Site 2, Tampa, Florida, United States
- Cara Therapeutics Study Site, Tampa, Florida, United States
- Cara Therapeutics Study Site, Albany, Georgia, United States
- Cara Therapeutics Study Site, Boston, Massachusetts, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03998163 on ClinicalTrials.govOther trials for Uremic pruritus
Additional recruiting or active studies for the same condition.